All In MedTech

Device Trial Radar · NCT02572557

TruFreeze Cryotherapy Central Airway Disease

A Prospective Evaluation of Spray Cryotherapy in Patients With Malignant and Benign Central Airway Disease

Last checked: Nov 20, 2026Latest source record: May 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Dec 2016

Primary completion

Dec 2021

Study completion Dec 2021

Sponsor

Lead sponsor
University Medical Center GroningenAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 9, 2015

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Rationale: Spray cryotherapy (SCT) using liquid nitrogen has been safely and effectively used in the esophagus, airways and pleura. Treatment with SCT for central airway stenosis may provide an effective, and more durable and perhaps safer alternative to the current therapeutic modalities. Objectives: 1. To investigate the feasibility of using Spray cryotherapy (SCT) for the treatment of malignant and benign central airway disease. 2. To investigate the safety of using Spray cryotherapy (SCT) for the treatment of malignant and benign central airway disease. 3. To investigate the efficacy of using Spray cryotherapy (SCT) for the treatment of malignant and benign central airway disease. Study design: This study will be a prospective, single arm, open label intervention study performed at the University Medical Center Groningen, The Netherlands Study population: The study population exists of 25 patients with malignant or benign central airway disease. Patients in which current treatment options are regarded to be suboptimal can be included in the study. Intervention: TruFreeze Spray CryoTherapy Main study parameter: Feasibility is defined as being able to apply the SCT as planned in one, or more bronchoscopies according to the instructions for use (IFU). Secondary study parameters: Safety will be assessed by capturing all adverse events (AEs) that occur 1) during the SCT procedure, and 2) all AEs that occur until hospital discharge. Efficacy will be measured using 1) patient reported outcomes (questionnaires), 2) percentage improvement in airway stenosis, 3) durability of treatment effect, 4) need to re-intervene with other therapies because of treatment failure. Nature and extent of the burden, risks and benefit associated with participation. Patients that will be recruited and participate in this prospective clinical trial have a severe central airway disease which is highly symptomatic for which current available therapies are either very difficult to perform, are hazardous, have no real benefit, or just simply not available yet. The current treatment risks of this patient group are high, especially in the patients where the airway patency is at risk. The main additional risk associated with the use of SCT is the occurrence of a pneumothorax. Patients participating will adhere to their current medical care, with the one addition of a voluntary follow-up bronchoscopy after SCT.

Conditions

  • Airway Obstruction

Interventions

  • TruFreeze Spray CryoTherapyDevice

    TruFreeze Spray CryoTherapy using liquid nitrogen

  • Liquid nitrogenDrug

    TruFreeze Spray CryoTherapy using liquid nitrogen

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of procedures in which SCT was applied as planned [Feasibility]Time frame: During bronchoscopy procedure
  2. Adverse events during procedure [Safety]Time frame: During bronchoscopy procedure
  3. Adverse events during hospital admission [Safety]Time frame: Up to 5 days after treatment

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.